What to Know About Genvoya (Elvitegravir, Cobicistat, Emtribitabine, Tenofovir AF)

Quad Drug Used to Treat HIV Infection

By
James Myhre & Dennis Sifris, MD
James Myhre & Dennis Sifris, MD
Dennis Sifris, MD, is an HIV specialist and Medical Director of LifeSense Disease Management. James Myhre is an American journalist and HIV educator.
Learn about our editorial process
Updated on September 06, 2021
Medically reviewed
Verywell Health articles are reviewed by board-certified physicians and healthcare professionals. Medical Reviewers confirm the content is thorough and accurate, reflecting the latest evidence-based research. Content is reviewed before publication and upon substantial updates. Learn more.
 by
Latesha Elopre, MD, MSPH
Elopre
Medically reviewed by Latesha Elopre, MD, MSPH

Latesha Elopre, MD, is a board-certified internist specializing in HIV. She is an assistant professor of infectious diseases at the University of Alabama at Birmingham.

Learn about our Medical Review Board
Table of Contents
View All
Table of Contents

Genvoya, also referred to as the Quad pill, is an all-in-one tablet used to treat HIV in adults and older children. Taken daily, Genvoya is comprised of four different antiretroviral drugs:

Genvoya is the first combination pill to use TAF, an "improved" version of tenofovir disoproxil fumarate (TDF) found in the drugs Truvada, Atripla, and Complera. As such, Genvoya can be considered an improvement on Stribild, the single-tablet formulation comprised of elvitegravir + cobicistat + emtricitabine + TDF. 

Person holding a pill
Gilead Sciences

TAF differs from TDF in that it is a prodrug, meaning a substance that is metabolized in the body to produce a drug. Because of this, TAF requires a far smaller dose and is less likely to cause kidney impairment, which is experienced by some users of TDF.

Antiretroviral drugs do not cure HIV. Instead, the drugs work by blocking a stage in the virus's replication cycle. By doing so, the virus can be suppressed to undetectable levels and prevent disease progression.

With Genvoya, two stages are blocked: reverse transcription, in which viral RNA is converted into DNA, and integration, in which the DNA is integrated into the host cell's nucleus to "hijack" the genetic machinery so that the virus can churn out new copies of itself.

Uses

Genvoya is used to treat HIV infection. The fixed-dose combination tablet was approved by the Food and Drug Administration in November 2015 for use in adults and children 12 and over who have never been on antiretroviral therapy and weigh over 77 pounds (35 kilograms).

Because the Genvoya dose is fixed and cannot be modified, Genvoya cannot be used in children under 12 or those under 77 pounds due to the risk of drug toxicity.

Genvoya can also be used to replace an antiretroviral drug regimen as long as the person has an undetectable viral load.

There are no off-label uses for Genvoya or generic versions of the drug.

Before Taking

Before taking Genvoya, your healthcare provider will order tests if you have never been on antiretrovirals or are changing treatment. The primary aim of the tests is to ensure you are not resistant to any of the drugs in Genvoya (or any other antiretroviral therapy).

Because drug resistance can be transmitted, meaning passed from one person to the next, it is possible for a newly infected person to be resistant to certain antiretroviral drugs. The same can occur in anyone previously exposed to antiretrovirals, during which resistance can develop naturally over time.

The following tests can identify resistant mutations or the virus's susceptibility to various antiretroviral drugs:

  • Genetic resistance testing: A blood test that can identify the number and types of mutations that confer resistance
  • Phenotypic testing: A blood test used to isolate the virus so that it can be exposed to all available antiretroviral drugs to see which ones work best

Precautions and Contraindications

Genvoya is contraindicated for use in anyone who has had a prior hypersensitive reaction to any of the drugs contained in the tablet.

Although Genvoya places less stress on the kidneys than TDF-based therapies, it is still used with caution in people with pre-existing kidney problems. Due to the lack of research, the FDA advises against the use of Genvoya in people with an estimated creatinine clearance below 30 milliliters per minute (mL/min).

Genvoya may also cause bone mineral loss. While this is generally not a problem for most people, bone mineral density (BMD) tests should be performed in people with osteoporosis or a history of pathologic bone fractures to ensure they are appropriate candidates for the drug.

Other Combination Antiretroviral Drugs

In addition to Genvoya, there are 12 other combination drugs that can be taken in a once-daily dose:

In January 2021, the FDA approved the first once-monthly antiretroviral combination regimen called Cabenuva, comprised of separate injectable doses of the drugs cabotegravir and rilpivirine.

Dosage

Genvoya is manufactured as a green, oblong, film-coated tablet embossed with "GSI" on one side and "510" on the other. Each tablet contains 150 milligrams (mg) of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 10 mg of TAF.

Genvoya is taken by mouth once daily with food. It should not be taken with any other antiretroviral drug used to treat HIV.

How to Take and Store

Elvitegravir requires food, specifically fats, for the drug to be properly absorbed in the gut. A high-fat meal is preferable to a low-fat meal.

Genvoya can be stored at room temperature, ideally at or below 86 degrees F (30 degrees C). It is best to keep the tablets in their original light-resistant container in a dark, cool drawer or cabinet. Avoid storing Genvoya on a sunny windowsill or in your car's glove compartment. Discard any pills that have expired.

If you miss a dose of Genvoya, take it as soon as you remember. If it is near the time of your next dose, skip the original dose and continue as normal. Do not double up doses.

Side Effects

Genvoya is associated with fewer side effects than many of the earlier generation antiretroviral drugs. When they do occur, they tend to be mild and transient, resolving within one to two weeks of starting treatment.

Common

According to premarket research, the most common side effects of Genvoya use were (by order of frequency):

  • Nausea (10% of users)
  • Diarrhea (7% of users)
  • Headache (6% of users)
  • Fatigue (5% of users)

Severe

In rare instances, Genvoya has been known to cause severe side effects, leading to serious and potentially life-threatening complications such as:

  • Kidney failure, most commonly in people with pre-existing kidney dysfunction
  • Hepatomegaly, the abnormal enlargement of the liver associated with NRTIs, most commonly in people with pre-existing liver disease
  • Osteomalacia, the softening of bone associated with tenofovir use
  • Lactic acidosis, the potentially life-threatening build-up of lactic acid in the bloodstream

Warnings and Interactions

Genvoya carries a black box warning advising consumers of the risk of hepatitis B exacerbations (flare-ups) in people coinfected with HIV and hepatitis B. Because tenofovir has anti-hepatitis B effects, the discontinuation of Genvoya may cause an acute and sometimes severe flare-up of hepatitis symptoms. If treatment is discontinued, liver function should be monitored and anti-hepatitis B treatment started should a flare-up occur.

Although Genvoya is generally considered safe during pregnancy, speak with your healthcare provider to fully weigh the benefits and risks of treatment if you are pregnant or planning to get pregnant. Animal studies have failed to show a risk of fetal harm; however, well-controlled studies in humans are lacking.

Drug Interactions

Genvoya is known to interact with many drugs due to the competition for a liver enzyme called cytochrome P450 (CYP450). This is an enzyme that many drugs, including Genvoya, rely upon for metabolization.

Taking other drugs that are strong CYP450 inducers can lead to dramatic drops in the concentration of Genvoya, reducing its effectiveness and increasing the risk of treatment failure.

Genvoya should not be taken with the following drugs or supplements:

  • Antipsychotics: Orap (pimozide)
  • Benzodiazepines: Halcion (triazolam), Versed (midazolam)
  • Gastrointestinal motility drugs: Propulsid (cisapride)
  • Hepatitis B drugs: Hepsera (adefovir)
  • Migraine medications: DHE 45 (dihydroergotamine), Ergostat (ergotamine), Migergot (caffeine + ergotamine), Medihaler Ergotamine, Methergine (methylergotamine), and others
  • Prostate medications: Uroxatral (alfuzosin)
  • Pulmonary hypertension drugs: Revatio (sildenafil)
  • St. John's wort
  • Statin drugs: Mevacor (lovastatin), Pravachol (pravastatin), Zocor (simvastatin), and others
  • Tuberculosis drugs: Mycobutin (rifabutin), Rifater (rifampin + isoniazid + pyrazinamide), Rifamate (rifampin + isoniazid), Rifadin (rifampin), Priftin (rifapentine), and others

Other drugs can interact with Genvoya and may require a drug substitution, dosage reduction, or the separation of doses by several hours.

To avoid interactions, always advise your healthcare provider about any drugs you take, whether they are prescription, over-the-counter, herbal, nutritional, or recreational.

Was this page helpful?
6 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.

  1. Buti M, Riveiro-Barcelia M, Esteban R. Tenofovir alafenamide fumarate: A new tenofovir prodrug for the treatment of chronic hepatitis B infection. J Infect Dis. 2017 Nov 16;216(suppl_8):S792-6. doi:10.1093/infdis/jix135

  2. Gilead Sciences. Package label - Genvoya.

  3. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Laboratory testing for initial assessment and monitoring of patients with HIV receiving antiretroviral therapy.

  4. U.S. Department of Health and Human Services. FDA-approved HIV medications.

  5. U.S. Food and Drug Administration. FDA approves Cabenuva and Vocabria for the treatment of HIV-1 infection.

  6. Shioma M, Matsuki S, Ikeda A, et al. Effects of a protein-rich drink or a standard meal on the pharmacokinetics of elvitegravir, cobicistat, emtricitabine and tenofovir in healthy Japanese male subjects: A randomized, three-way crossover study. J Clin Pharmacol. 2014;54(6):640-8. doi:10.1002/jcph.283

Related Articles